To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA
assay directed at a BCa-associated diagnostic signature in voided urine samples of
patients with microscopic hematuria.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03193541.
Locations matching your search criteria
United States
Texas
Dallas
UT Southwestern/Simmons Cancer Center-DallasStatus: Active
Name Not Available
Hematuria is the most common presentation of BCa with 8% of patients with microscopic
hematuria harboring BCa. VUC is the most widely used urine-based assay for detecting BCa;
however, it fails to detect approximately 50% of low-grade or early stage BCa when it is
most curable. Because of this severe limitation, patients with hematuria will undergo an
invasive examination of the urinary bladder, where a miniature camera is inserted into
the bladder.
We propose to improve the non-invasive detection of BCa by further validating a multiplex
ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of
patients with microscopic hematuria.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationCedars Sinai Medical Center
Principal InvestigatorHideki Furuya
